Physician profile
Peter V Leoni
NPI 1316907082
$25,961.24
in general payments reported to CMS, 2019-2025
15 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $25K · 2021: $27.91 · 2022: $256 · 2023: $337 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $24,631.44 | 2020-2021 | |
| Medtronic, INC. | $354.93 | 2022-2023 | In.Pact Admiral |
| Boston Scientific Corporation | $222.14 | 2025 | Eluvia, General - Therapies |
| Musculoskeletal Transplant Foundation INC. | $170.60 | 2019 | |
| Mimedx Group, INC. | $144.26 | 2025 | |
| Organogenesis INC. | $113.91 | 2022 | |
| Cook Medical LLC | $77.13 | 2023 | Zenith Alpha |
| Sobi, INC | $44.72 | 2025 | |
| Janssen Biotech, INC. | $38.41 | 2025 | Rybrevant |
| Incyte Corporation | $36.94 | 2023-2025 | Monjuvi, Zynyz |
| Tela Bio, INC. | $33.70 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Seagen INC. | $27.88 | 2023 | Adcetris |
| Iovance Biotherapeutics, INC. | $25.39 | 2025 | Amtagvi |
| Astrazeneca Pharmaceuticals LP | $21.58 | 2025 | Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $18.21 | 2025 | Iclusig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Leoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.